CL2022000118A1 - Formulaciones orales de edaravone y método de fabricación de las mismas. - Google Patents

Formulaciones orales de edaravone y método de fabricación de las mismas.

Info

Publication number
CL2022000118A1
CL2022000118A1 CL2022000118A CL2022000118A CL2022000118A1 CL 2022000118 A1 CL2022000118 A1 CL 2022000118A1 CL 2022000118 A CL2022000118 A CL 2022000118A CL 2022000118 A CL2022000118 A CL 2022000118A CL 2022000118 A1 CL2022000118 A1 CL 2022000118A1
Authority
CL
Chile
Prior art keywords
edaravone
manufacture
oral formulations
less
concentration
Prior art date
Application number
CL2022000118A
Other languages
English (en)
Spanish (es)
Inventor
Manappa Badiger Aravind
Ketanbhai Choksi Rakshit
Naginbhai Patel Bhavesh
Mahendrabhai Shah Dharmesh
Purshottambhai Patil Mayurkumar
Atulkumar Shah Jigar
Dilipbhai Trivedi Madhavkumar
Jayantilal Thakkar Vishal
Ashwinbhai Vora Pratik
Natvarlal Jadav Nirav
Original Assignee
Bdr Pharmaceuticals International Private Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bdr Pharmaceuticals International Private Ltd filed Critical Bdr Pharmaceuticals International Private Ltd
Publication of CL2022000118A1 publication Critical patent/CL2022000118A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2022000118A 2019-07-18 2022-01-17 Formulaciones orales de edaravone y método de fabricación de las mismas. CL2022000118A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN201921028874A IN201921028874A (cg-RX-API-DMAC7.html) 2019-07-18 2019-07-18

Publications (1)

Publication Number Publication Date
CL2022000118A1 true CL2022000118A1 (es) 2023-03-10

Family

ID=74210260

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022000118A CL2022000118A1 (es) 2019-07-18 2022-01-17 Formulaciones orales de edaravone y método de fabricación de las mismas.

Country Status (9)

Country Link
US (1) US12691099B2 (cg-RX-API-DMAC7.html)
EP (1) EP3989968A4 (cg-RX-API-DMAC7.html)
BR (1) BR112022000914A2 (cg-RX-API-DMAC7.html)
CL (1) CL2022000118A1 (cg-RX-API-DMAC7.html)
IN (1) IN201921028874A (cg-RX-API-DMAC7.html)
MX (1) MX2022000762A (cg-RX-API-DMAC7.html)
PH (1) PH12022550117A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021009775A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202201541B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021008197A2 (pt) 2018-11-02 2021-08-03 Mitsubishi Tanabe Pharma Corporation suspensão de edaravone para administração oral
US11826352B2 (en) 2018-11-02 2023-11-28 Mitsubishi Tanabe Pharma Corporation Edaravone suspension for oral administration
JP2025530029A (ja) * 2022-08-18 2025-09-10 ビーディーアール ファーマシューティカルズ インターナショナル プライベート リミテッド エダラボンの経口製剤およびその改良された製造方法
WO2024172852A1 (en) 2023-02-16 2024-08-22 Slayback Pharma Llc Stable pharmaceutical compositions of edaravone
WO2026028170A1 (en) * 2024-08-02 2026-02-05 Lupin Limited Pharmaceutical composition of edaravone

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE473214C (de) 1925-10-22 1929-12-04 I G Farbenindustrie Akt Ges Verfahren zur Herstellung von 1-Phenyl-3-methyl-5-pyrazolon
ES2248144T3 (es) 2000-10-24 2006-03-16 Mitsubishi Pharma Corporation Medicamentos para tratar la esclerosis lateral amiotrofica (ela).
CN1440749A (zh) * 2003-03-24 2003-09-10 南昌弘益科技有限公司 易达拉封注射剂及其制备工艺——治疗急性脑梗塞
CN1241565C (zh) 2003-04-16 2006-02-15 浙江震元制药有限公司 依达拉奉药物组合物及制备
WO2009067343A1 (en) 2007-11-21 2009-05-28 Teikoku Pharma Usa, Inc. Pyrazolone derivative emulsion formulations
CN101953832B (zh) 2010-08-10 2012-02-15 南京师范大学 β-环糊精包合依达拉奉的口服药物组合物及其制备方法
CN102349893A (zh) * 2011-08-19 2012-02-15 福建天泉药业股份有限公司 依达拉奉药物组合物
CN105878171A (zh) * 2014-12-22 2016-08-24 南京海恒医药科技有限公司 一种依达拉奉新制剂及其制备方法
CN109125261B (zh) 2016-03-16 2021-11-30 苏州澳宗生物科技有限公司 依达拉奉剂型
CN107773545A (zh) * 2016-08-29 2018-03-09 烟台益诺依生物医药科技有限公司 依达拉奉与(+)‑2‑莰醇的舌下用药物组合物
EP3785703A1 (en) 2017-01-17 2021-03-03 Treeway TW001 B.V. Treatment comprising oral or gastric administration of edaravone
BR112019014712A2 (pt) 2017-01-17 2020-02-18 Treeway Tw001 B.V. Tratamento médio que compreende a administração entérica de edaravona
RU2693627C2 (ru) * 2017-11-03 2019-07-03 Общество С Ограниченной Ответственностью "Валента - Интеллект" Комбинации эдаравона для лечения ишемических повреждений мозга
WO2019213333A1 (en) * 2018-05-04 2019-11-07 Carnot2, Llc Combination therapies with edaravone and prodrugs of edaravone that are orally bioavailable and have altered pharmacokinetic properties
BR112021008197A2 (pt) * 2018-11-02 2021-08-03 Mitsubishi Tanabe Pharma Corporation suspensão de edaravone para administração oral

Also Published As

Publication number Publication date
US20220409588A1 (en) 2022-12-29
US12691099B2 (en) 2026-07-28
EP3989968A4 (en) 2023-07-12
MX2022000762A (es) 2022-04-01
ZA202201541B (en) 2023-05-31
PH12022550117A1 (en) 2022-12-19
EP3989968A1 (en) 2022-05-04
IN201921028874A (cg-RX-API-DMAC7.html) 2021-01-22
BR112022000914A2 (pt) 2022-03-08
WO2021009775A1 (en) 2021-01-21

Similar Documents

Publication Publication Date Title
CY1126062T1 (el) Σταθερη φαρμακοτεχνικη μορφη anti-ifnar1
PE20180411A1 (es) Formulaciones farmaceuticas que comprenden tenofovir y emtricitabina
CY1126067T1 (el) Συντηγμενες πυρρολινες που δρουν σαν ειδικοι για ουβικιτινη αναστολεις πρωτεασης 30 (usp30)
TW200621317A (en) Pharmaceutical composition
MX2021007392A (es) Regimen de dosificacion y combinacion farmaceutica que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona.
EA201992116A1 (ru) Фармацевтические составы флороглюцинола и триметилфлороглюцинола
MX2019006670A (es) Composiciones que comprenden profarmacos de metilfenidato, procedimientos para la elaboracion y uso de los mismos.
MX2023013515A (es) Inhibidores de la interaccion de menina-mll.
CY1124115T1 (el) Η χρηση τριβενζοϊκου γλυκερυλιου που περιεχει συνθεση σε νευροεκφυλιστικες διαταραχες
MX2022000762A (es) Formulaciones orales de edaravone y metodo de fabricacion de las mismas.
EA202192925A1 (ru) Твердые формы ингибитора glyt1
MX385518B (es) FORMULACIÓN QUE TIENE CARACTERÍSTICAS MEJORADAS DE LIBERACIÓN DE FÁRMACOS pH DEPENDIENTES, QUE CONTIENEN ESOMEPRAZOL O UNA DE SUS SALES FARMACÉUTICAS ACEPTABLE.
CO6300935A2 (es) Formulaciones orales e inyectables de compuestos de tetraciclina
JOP20240196A1 (ar) تركيبات تحتوي على أتيكابرانت
EA201792237A1 (ru) Фармацевтические составы
ECSP044979A (es) Uso de bibn4096 en combinación con otros fármacos antimigrañosos para el tratamiento de migraña
EA201991286A1 (ru) Твердая фармацевтическая композиция для перорального применения, содержащая тенофовир и эмтрицитабин
EA201892842A1 (ru) Фармацевтические композиции, включающие сафинамид
MX2019015869A (es) Nuevas formulaciones orales de belinostat.
TR201717703A2 (tr) Api̇ksaban formülasyonlari
CO2020001742A2 (es) Composiciones sólidas orales de betahistina de liberación prolongada no pulsátil
EA202192118A1 (ru) Фармацевтическая композиция, содержащая ацетаминофен и ибупрофен
FR2869615B1 (fr) Derives de l'acide butanoique, procedes pour leur preparation, compositions pharmaceutiques les contenant et leurs applications therapeutiques
JOP20240074A1 (ar) تركيبات إنزالوتاميد سائلة فموية
EA200601015A1 (ru) Пероральные композиции дезоксипеганина и их применение